
==== Front
BMC Cancer
BMC Cancer
BMC Cancer
1471-2407
BioMed Central London

12901
10.1186/s12885-024-12901-7
Research
The causal relationship between CSF metabolites and GBM: a two-sample mendelian randomization analysis
Bao Haijun 12
Chen Yiyang 1
Meng Zijun 1
Chu Zheng chuzheng@xzhmu.edu.cn

12
1 grid.417303.2 0000 0000 9927 0537 Department of Forensic Medicine, First College for Clinical Medicine, Xuzhou Medical University, 84 West Huaihai Rd, Xuzhou, Jiangsu 221000 China
2 Jiangsu Medical Engineering Research Center of Gene Detection, Xuzhou, Jiangsu China
9 9 2024
9 9 2024
2024
24 111925 3 2024
4 9 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by-nc-nd/4.0/ Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
Background

Glioblastoma multiforme (GBM) is a highly aggressive primary malignant brain tumor characterized by rapid progression, poor prognosis, and high mortality rates. Understanding the relationship between cerebrospinal fluid (CSF) metabolites and GBM is crucial for identifying potential biomarkers and pathways involved in the pathogenesis of this devastating disease.

Methods

In this study, Mendelian randomization (MR) analysis was employed to investigate the causal relationship between 338 CSF metabolites and GBM. The data for metabolites were obtained from a genome-wide association study summary dataset based on 291 individuals, and the GBM data was derived from FinnGen included 91 cases and 174,006 controls of European descent. The Inverse Variance Weighted method was utilized to estimate the causal effects. Supplementary comprehensive assessments of causal effects between CSF metabolites and GBM were conducted using MR-Egger regression, Weighted Median, Simple Mode, and Weighted Mode methods. Additionally, tests for heterogeneity and pleiotropy were performed.

Results

Through MR analysis, a total of 12 identified metabolites and 2 with unknown chemical properties were found to have a causal relationship with GBM. 1-palmitoyl-2-stearoyl-gpc (16:0/18:0), 7-alpha-hydroxy-3-oxo-4-cholestenoate, Alpha-tocopherol, Behenoyl sphingomyelin (d18:1/22:0), Cysteinylglycine, Maleate, Uracil, Valine, X-12,101, X-12,104 and Butyrate (4:0) are associated with an increased risk of GBM. N1-methylinosine, Stachydrine and Succinylcarnitine (c4-dc) are associated with decreased GBM risk.

Conclusion

In conclusion, this study sheds light on the intricate interplay between CSF metabolites and GBM, offering novel perspectives on disease mechanisms and potential treatment avenues. By elucidating the role of CSF metabolites in GBM pathogenesis, this research contributes to the advancement of diagnostic capabilities and targeted therapeutic interventions for this aggressive brain tumor. Further exploration of these findings may lead to improved management strategies and better outcomes for patients with GBM.

Supplementary Information

The online version contains supplementary material available at 10.1186/s12885-024-12901-7.

Keywords

Cerebrospinal fluid
Metabolite
GBM
Mendelian randomization
issue-copyright-statement© BioMed Central Ltd., part of Springer Nature 2024
==== Body
pmcIntroduction

Glioblastoma multiforme (GBM) is one of the most aggressive primary malignant brain tumors, characterized by rapid progression, poor prognosis, and high mortality rates [1]. According to the 2016 WHO classification, gliomas are divided into four grades: low-grade gliomas (LGG grades I and II) and high-grade gliomas (HGG grades III and IV) [2]. GBM, the most malignant subtype, accounts for over 50% of all gliomas and more than 15% of primary brain tumors [3]. Due to its immunosuppressive microenvironment and tendency for recurrence, GBM stands out as one of the most challenging tumors, imposing a significant societal burden.

Cerebrospinal fluid (CSF) envelops the cerebral and spinal regions within the meningeal cavities, playing a crucial role in maintaining brain homeostasis, providing nutrients, and clearing waste. Thanks to the presence of the blood-brain barrier, CSF maintains its distinctive environment, safeguarding the normal functioning of neurons. Due to their direct exposure to GBM, CSF metabolites hold the potential to mirror metabolic alterations linked to tumor initiation, presence, and progression [4]. GBM, as a highly invasive brain tumor, can disrupt the normal flow and composition of CSF, leading to increased intracranial pressure and hydrocephalus. Additionally, GBM cells can infiltrate the soft meninges and spread along the CSF pathways [5]. Therefore, CSF analysis, including cytology and molecular spectrum analysis, is pivotal for diagnosing and monitoring GBM, as it may contain tumor cells and biomarkers reflecting the disease state. Understanding the dynamic interplay between GBM and CSF is crucial for enhancing diagnostic and therapeutic strategies against this devastating disease.

Studying CSF presents both challenges and valuable opportunities in understanding various neurological disorders. One of the primary hurdles lies in obtaining CSF samples, typically acquired through invasive procedures like lumbar punctures, posing risks and discomfort to patients. Consequently, most human metabolomics research has focused on more accessible sample types such as blood or urine. Furthermore, CSF composition is dynamic, influenced by factors like age, gender, and disease status, making standardization and interpretation complex [6]. Despite these challenges, researching CSF holds immense value. CSF serves as a direct window into the central nervous system, reflecting biochemical, cellular, and molecular changes associated with neurological disorders like Alzheimer’s disease, multiple sclerosis, and brain tumors [7–9]. Analysis of CSF biomarkers provides diagnostic, prognostic, and therapeutic insights, aiding in disease detection, monitoring, and treatment response assessment. Rogachev et al. found that there were partial differences in the correlation of plasma and CSF metabolites between HGG and healthy control groups [4]. Ji et al. demonstrated that CSF metabolites could be used to predict glioma grade and leptomeningeal metastasis [10]. So, by overcoming technical barriers and leveraging the rich information provided by CSF, researchers can significantly enhance our understanding and management of neurological diseases, ultimately improving patient outcomes.

In this study, we employed Mendelian randomization (MR) analysis to investigate the causal relationship between CSF metabolites and GBM. MR is a robust epidemiological method that utilizes single nucleotide polymorphisms (SNPs) as instrumental variables (IVs), less susceptible to unmeasured confounders and reverse causality [11]. This study aims to elucidate potential disease mechanisms, identify novel therapeutic avenues, and provide insights for the diagnosis, treatment, and prevention of GBM.

Materials and methods

Study design

Our study provides an overview of two sample MR surveys used to explore the causal relationship between CSF metabolites and GBM. In MR studies, adherence to three fundamental instrumental variable (IV) assumptions is crucial: (1) genetic variants must correlate with the exposure; (2) these variants should be independent of confounding factors; and (3) they should exclusively impact the outcome through the exposure [11]. Strict quality control measures, including tests for multicollinearity and heterogeneity, were conducted to enhance the reliability of causal results.

CSF metabolites data synopsis

The exposure factor we studied is 338 CSF metabolites, based on a metabolome-wide association study by Panyard et al. [12]. In this study, a total of 291 independent samples of individuals of European descent were retained after quality control and further data cleaning steps. All participants were in a state of cognitive health when CSF was extracted. Among the 338 metabolites, 38 are still chemically undefined, whereas 296 have undergone chemical validation and are categorized into eight primary metabolic groups, encompassing amino acid, carbohydrate, cofactor and vitamin, energy, lipid, nucleotide, peptide, and xenobiotic metabolism.

GBM data synopsis

The outcome variable under scrutiny is GBM, for which the genome-wide association study (GWAS) summary dataset was sourced from FinnGen included 91 cases and 174,006 controls of European descent and comprised 16,380,303 SNPs.

Selection of IVs

SNPs are commonly used genetic variations in MR Analysis, reflecting DNA sequence diversity resulting from a single nucleotide change at the genomic level. In our study, we meticulously constructed a unique set of IVs for each of the 338 CSF metabolites. This approach was taken to ensure that the genetic associations specific to each metabolite were accurately represented. Firstly, considering the limited number of SNPs available to achieve genome-wide significance for metabolites, we relaxed the threshold by testing with a p-value set to less than 1 × 10^−5 [13]. Then, linkage disequilibrium criteria were set at r2 < 0.001 and a genetic distance of 10,000 kb, with highly correlated SNPs excluded to ensure the independence of included SNPs. Furthermore, to mitigate bias resulting from weak instrumentality, the F-value of each SNP was computed, and SNPs with an F-value < 10 were identified as weak instruments [14]. F = R2(N − 2)/(1 − R2), in which R2 and N denotes the proportion of variance explained by the chosen SNPs and the sample size of the GWAS for the SNP respectively. What’s more, we utilized the IEU OpenGWAS database to meticulously identify and exclude any SNPs that showed significant associations with potential confounders. Finally, project the SNPs related to CSF metabolites onto the GWAS merged data of GBM and extract the corresponding statistical parameters.

Statistical analysis

In this study, we employed the Inverse Variance Weighted (IVW), MR-Egger, and Weighted Median, Weighted mode, and Simple mode methods to estimate dependent effects. Given the IVW method’s superior test efficacy compared to other MR methods, we selected it as the primary method. The IVW method assumes the validity of all genetic variants as instrumental variables. It calculates causal effect values for individual instrumental variables using the ratio method, then combines each estimate through weighted linear regression to derive the total effect value. Nonetheless, there might be unidentified confounding variables leading to genetic pleiotropy and bias in effect size estimation. Therefore, MR-Egger regression and weighted median methods were employed as supplementary approaches to corroborate the causal impact of exposure on the outcome. The “leave-one-out” method was employed to identify any instrumental variables that could influence the estimation of causal effects. Horizontal pleiotropy was assessed using the Egger intercept, and the Mendelian randomization pleiotropy residual sum and outlier (MR-PRESSO) test was performed to identify and exclude SNPs that may be influenced by pleiotropy. Heterogeneity tests were conducted using the Cochran Q test to evaluate the diversity of the SNPs. All analyses were performed using the TwoSampleMR R packages in R software 4.4.1.

Results

After investigating the quality control of IVs, we identified 14 CSF metabolites associated with GBM, including 21–196 SNPs (with Stachydrine genetically represented by 21 SNPs and Butyrate (4:0) having the highest representation with 196 SNPs). The F-statistic data range for CSF metabolites is from 19.37 to 78.49, all exceeding a threshold greater than 10, indicating they are less likely to be influenced by instrument biases (Supplementary Table S1). Among the 14 CSF metabolites associated with GBM, there are 12 identified metabolites and 2 with unknown chemical properties. The identified metabolites chemically classify into lipids, vitamins, amino acids, nucleotides, energy and xenobiotics (Supplementary Table S2).

The causal relationship between the risk of GBM and 14 CSF metabolites is as follows (Fig. 1): 1-palmitoyl-2-stearoyl-gpc (16:0/18:0) (OR 1.661, 95% CI: 1.039–2.654, p = 0.034), 7-alpha-hydroxy-3-oxo-4-cholestenoate (7-HOCA) (OR 4.272, 95% CI: 1.335–13.673, p = 0.014), Alpha-tocopherol (12:0) (OR 1.693, 95% CI: 1.037–2.764, p = 0.035), Behenoyl sphingomyelin (d18:1/22:0) (OR 1.515, 95% CI: 1.120–2.051, p = 0.007), Cysteinylglycine (OR 1.361, 95% CI: 1.072–1.726, p = 0.011), Maleate (OR 1.517, 95% CI: 1.077–2.137, p = 0.017), N1-methylinosine (OR 0.467, 95% CI: 0.232–0.941, p = 0.033), Stachydrine (OR 0.738, 95% CI: 0.578–0.942, p = 0.015), Succinylcarnitine (c4-dc) (OR 0.328, 95% CI: 0.110–0.978, p = 0.046), Uracil (OR 5.053, 95% CI: 1.044–24.449, p = 0.044), Valine (OR 5.284, 95% CI: 1.170–23.868, p = 0.030), X-12,101 (OR 2.219, 95% CI: 1.148–4.290, p = 0.018), X-12,104 (OR 2.943, 95% CI: 1.023–8.463, p = 0.045), Butyrate (4:0) (OR 1.422, 95% CI: 1.063–1.904, p = 0.018).

Fig. 1 Forest plot of mendelian randomization estimates between CSF metabolites and GBM

In brief, the IVW-derived estimates demonstrated significance (p < 0.05), with a consistent direction and magnitude observed across IVW, MR-Egger, Weighted mode, Weighted median and Simple mode estimates (Supplementary Table S3). The conclusions of the other four methods remain largely consistent with those of the IWV method. Both the MR-Egger intercept test and the Cochran Q test strongly support the absence of pleiotropy and heterogeneity, except the Egger intercept of Behenoyl sphingomyelin (d18:1/22:0) showing pleiotropy (Table 1). Scatter plots for 14 identified CSF metabolites across various tests are displayed in Fig. 2. The leave-one-out analysis confirmed that excluding any single SNP did not introduce bias into the MR estimation (Supplementary Figure S1). The funnel plots are presented in Supplementary Figure S2.

Fig. 2 Scatter plots of 14 CSF metabolites related to the risk of GBM

Table 1 Pleiotropy and heterogeneity of MR

Exposure	Methods	Q	P	Intercept	P	MR-PRESSO	
1-palmitoyl-2-stearoyl-gpc (16:0/18:0)	IVW	54.099	0.807	0.051	0.517	0.836	
MR-Egger	54.523	0.820	
7-alpha-hydroxy-3-oxo-4-cholestenoate	IVW	15.375	0.804	-0.017	0.881	0.855	
MR-Egger	15.398	0.845	
Alpha-tocopherol	IVW	74.475	0.528	0.055	0.417	0.523	
MR-Egger	75.140	0.539	
Behenoyl sphingomyelin (d18:1/22:0)	IVW	26.463	0.921	-0.193	0.043	0.836	
MR-Egger	30.855	0.821	
Cysteinylglycine	IVW	36.107	0.930	0.027	0.760	0.947	
MR-Egger	36.201	0.942	
Maleate	IVW	23.340	0.837	0.115	0.222	0.845	
MR-Egger	24.890	0.810	
N1-methylinosine	IVW	45.034	0.708	0.091	0.308	0.706	
MR-Egger	46.095	0.704	
Stachydrine	IVW	16.860	0.599	-0.002	0.983	0.698	
MR-Egger	16.860	0.662	
Succinylcarnitine (c4-dc)	IVW	25.099	0.400	0.026	0.763	0.499	
MR-Egger	25.197	0.451	
Uracil	IVW	25.757	0.477	-0.072	0.598	0.554	
MR-Egger	26.042	0.516	
Valine	IVW	10.507	0.972	-0.007	0.857	0.980	
MR-Egger	10.510	0.981	
X-12,101	IVW	36.827	0.339	0.058	0.543	0.387	
MR-Egger	37.236	0.367	
X-12,104	IVW	19.289	0.736	0.079	0.458	0.791	
MR-Egger	19.858	0.754	
Butyrate (4:0)	IVW	180.845	0.742	0.006	0.932	0.761	
MR-Egger	180.852	0.758	

Discussion

Our study delved into the intricate relationship between CSF metabolites and GBM, shedding light on potential biomarkers and pathways implicated in the pathogenesis of this aggressive brain tumor. By investigating the relationship between CSF metabolites and GBM risk through MR analysis, we identified 14 CSF metabolites significantly associated with the risk of GBM. These metabolites encompass a variety of biochemical classes, including lipids, vitamins, amino acids, nucleotides, energy and xenobiotics, underscoring the multifactorial nature of GBM development and progression. Understanding the dynamic interplay between CSF metabolites and GBM not only enhances our diagnostic capabilities but also holds promise for the development of targeted therapeutic interventions aimed at disrupting key metabolic pathways implicated in GBM tumorigenesis and progression.

Lipids, including sterols, phospholipids, and diacyl/triacylglycerols, are components of biofilms, which emerge as pivotal players in the landscape of GBM research. Lipids serve not only as structural components of cell membranes but also as signaling molecules involved in various cellular processes, including proliferation, migration, and apoptosis. The dysregulation of lipid metabolism has been implicated in tumor initiation, progression, and therapy resistance, making lipid metabolites attractive candidates for biomarker discovery and therapeutic targeting in GBM [15]. So far, there have been no literature reports on the roles of 1-palmitoyl-2-steroyl-gpc (16:0/18:0) and Behenoyl sphingomyelin (d18:1/22:0) in cancer. We speculate that these two phospholipid metabolites may be associated with enhanced lipid synthesis and metabolism typically exhibited by cancer cells. Not only do they provide the structural support required for cancer cell proliferation, but they also participate in regulating cell signaling pathways and epigenetic events, promoting the survival and metastasis ability of cancer cells. Halama et al. have discovered that in colon and ovarian cancer, endothelial cells induce metabolic reprogramming by promoting the overexpression of glycerophospholipids and polyunsaturated fatty acids in cancer cells [16].

In our study, we are pioneering the association between 7-HOCA and GBM for the first time. 7-HOCA is the primary metabolite of oxysterol 27-hydroxycholesterol in the brain, and the increase of 7-HOCA in CSF has been shown to reflect blood-brain barrier damage [17, 18]. Feng et al. found that 7-HOCA is closely related to the occurrence of lung cancer, showing a significantly increased risk [19]. Combining our research findings, 7-HOCA may play a significant role in the development of cancer. Butyrate (4:0) is the salt form of butyric acid, which stands as a significant byproduct in fatty acid metabolism. In vivo, butyric acid can be generated through various pathways, including its production from the metabolism of fatty acids or its fermentation from dietary fiber by intestinal microbiota. Once produced, butyric acid actively participates in the regulation and modulation of lipid metabolism, influencing the synthesis, breakdown, and utilization of fats in the body. Tumor cells can obtain fatty acids through lipolysis to support their growth. During periods of adequate nutritional supply, fatty acids are stored in adipose tissue as triglycerides (TG), which are broken down to release fatty acids when energy levels are low. Recent studies have revealed the significant role of butyrate salts in the occurrence and progression of colorectal and lung cancers [20]. However, this is the first report on the relationship between butyrate salts and GBM. We are also presenting, for the first time, the causal relationship between maleate in CSF and GBM. Maleate is a salt form of malic acid, present in the human body as a metabolite or dietary source. Further research is needed to understand its involvement in the onset and progression of GBM.

The importance of amino acid metabolism in GBM lies in its role as the building blocks of proteins. Amino acids not only provide essential materials for cell growth and proliferation but also participate in regulating cellular signaling, gene expression, and metabolic pathways. GBM cells typically exhibit high metabolic activity, leading to an increased demand for amino acids. Therefore, abnormalities in amino acid supply and metabolism may influence the development and progression of glioblastoma. In our study, valine and cysteinylglycine was found to have a positive relationship with GBM. Similar to our results, Yao et al. found that the valine, leucine, and isoleucine biosynthesis metabolic pathway can be used for screening and diagnosis of ovarian cancer [21]. Valine, leucine and isoleucine constitute the group of branched-chain amino acids (BCAAs), which can be utilized and processed by astrocytes to perform various functions, including serving as fuel materials for brain energy metabolism [22]. The diagnostic role of valine metabolites in cancer has also been found in saliva. In another study, valine was found to play a dominant role in diagnosing multiple cancers through saliva [23]. Cysteinylglycine, produced during the breakdown of glutathione, has been proposed as a prooxidant, contributing to oxidative stress and lipid peroxidation, which are implicated in the development of human cancers. Consistent with our results, Lin et al. found that the increase of cysteinylglycine level was associated with the increased risk of breast cancer in the high oxidative stress group of middle-aged and elderly women [24]. However, there are also studies suggesting the opposite perspective. For instance, Miranti et al. found a negative correlation between serum cysteinylglycine and esophageal adenocarcinoma [25]. For understanding and intervening in the metabolic characteristics and therapeutic mechanisms of GBM, in-depth investigation into the role of amino acid metabolism is crucial.

As the fundamental substances that ensure the structure of DNA, the metabolism of nucleotides is closely intertwined with the initiation and progression of tumors. As shown in this study, uracil may act as a metabolite and participant in the onset and progression of tumors. UPP1, as a critical enzyme in uracil metabolism, catalyzes the dephosphorylation of uridine to uracil and ribose-1-phosphate. Its activation of the AKT signaling pathway can enhance tumorigenesis and resistance to anticancer drugs [26]. N1-methylinosine is a known modification of ribonucleosides, formed by adding a methyl group to the N1 position of the purine ring of a nucleotide. This methylation modification typically occurs within RNA molecules. In biological organisms, methylation modifications of ribonucleosides are common epigenetic regulatory mechanisms that can influence RNA stability, translation, and interactions. Studies by Li et al. detected N1-methylinosine in urine samples from cancer patients, suggesting its potential as a biomarker for cancer [27]. The presence of N1-methylinosine may indicate abnormalities in ribonucleoside metabolism within cells, which could be associated with the development and progression of cancer.

In our study, except N1-methylinosine, another two metabolites that showed a negative causal relationship with GBM were Stachydrine and Succinylcarnitine (c4-dc). Stachydrine is renowned for its antioxidant and anti-inflammatory properties [28]. Consistent with our results, some studies have demonstrated that Stachydrine can inhibit the proliferation of breast cancer and liver cancer cells, while inducing apoptosis, autophagy, and cellular senescence. Its mechanisms of action may include inhibiting survival signaling pathways such as Akt and ERK, as well as regulating the expression of cell cycle proteins [29, 30]. Liu et al. found that Stachydrine may prevent liver damage by attenuating inflammatory responses, inhibiting the ERK and AKT pathways, and suppressing the expression of macrophage stimulating protein [31]. Succinylcarnitine is an intermediate in the tricarboxylic acid (TCA) cycle and amino acid-based energy metabolism, responsible for fatty acid β-oxidation and mitochondrial function, serving as an energy-related metabolic product [32]. An MR study identified maternal succinylcarnitine during pregnancy as a significant factor contributing to the risk of congenital heart disease in offspring [33]. Kim et al. found that the decrease in plasma succinylcarnitine levels was associated with the inhibition of prostate tumor growth by a whole walnut diet, possibly achieved through influencing cellular energy metabolism status and regulating relevant gene expression [34]. However, further research is needed to elucidate the specific mechanisms of these two CSF metabolites.

Several limitations exist within our study. the Pleiotropy test result of Behenoyl sphingomyelin (d18:1/22:0) was less than 0.05, indicating the presence of pleiotropy. However, further SNP screening was performed using MR-PRESSO, but the results showed no SNPs that needed to be removed. There are many possible reasons for this result, such as sample size, insufficient statistical power, complexity of pleiotropy, and methodological limitations. Therefore, it is emphasized that readers need to be cautious when reviewing the results, which does not mean that there is no pleiotropy, but may be due to the influence of the above factors. Additionally, our study may have another important limitation, which is the lack of research on the potential correlation of metabolites at SNP and phenotype levels. This oversight may have implications for the interpretation of our findings, as unaccounted correlations could influence the results of the Mendelian Randomization analysis.

These findings from our study open several avenues for future research. It is essential to delve into the mechanistic roles of the identified CSF metabolites in GBM biology, exploring their interactions with cellular pathways and the tumor microenvironment. Additionally, longitudinal studies are needed to understand the dynamics of these metabolites over the course of the disease and in response to treatments. Investigating the generalizability of our findings across diverse populations and the integration of metabolomics data with other omics platforms will be critical for identifying robust biomarker panels. Furthermore, the potential of these metabolites as therapeutic targets should be rigorously tested in preclinical models to advance towards novel treatment strategies for GBM.

Conclusion

In conclusion, our study provides valuable insights into the intricate relationship between CSF metabolites and GBM, shedding light on potential biomarkers and pathways involved in the pathogenesis of this aggressive brain tumor. Through MR analysis, we identified 14 CSF metabolites significantly associated with GBM risk, spanning various biochemical classes such as lipids, vitamins, amino acids, nucleotides, energy, and xenobiotics. This underscores the multifactorial nature of GBM development and progression. Our findings highlight the importance of understanding the dynamic interplay between CSF metabolites and GBM, not only for enhancing diagnostic capabilities but also for potentially developing targeted therapeutic interventions aimed at disrupting key metabolic pathways implicated in GBM tumorigenesis and progression.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary Material 1

Supplementary Material 2

Supplementary Material 3

Supplementary Material 4

Supplementary Material 5

Acknowledgements

The authors thank all the participants and researchers who contributed and collected data.

Author contributions

HjB: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Projection administration; Software, Validation, Writing – original draft. YyC: Formal analysis, Investigation, Writing – original draft. ZjM: Conceptualization, Data curation, Investigation, Writing – review & editing. ZC: Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Projection administration; Software, Validation, Writing – review & editing.

Funding

This research was supported by Research Foundation for Talented Scholars of Xuzhou Medical University (D2021011).

Data availability

The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author.

Declarations

Ethical approval

All data analyzed in this study were sourced from publicly available databases. Ethical approval was secured for each cohort, and informed consent was obtained from all participants prior to their involvement. Written informed consent was provided by the patients/participants for their participation in this study.

Consent for publication

Not Applicable.

Conflict of interest

The authors declare no competing interests.

Abbreviations

7-HOCA 7-alpha-hydroxy-3-oxo-4-cholestenoate

CSF Cerebrospinal fluid

GBM Glioblastoma multiforme

GWAS Genome-wide association study

IVs Instrumental variables

MR Mendelian randomization

SNPs Single nucleotide polymorphisms

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. Ilkhanizadeh S Glial progenitors as targets for transformation in glioma Adv Cancer Res 2014 121 1 65 10.1016/B978-0-12-800249-0.00001-9 24889528
Ilkhanizadeh S, et al. Glial progenitors as targets for transformation in glioma. Adv Cancer Res. 2014;121:1–65.24889528 10.1016/B978-0-12-800249-0.00001-9
2. Louis DN The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary Acta Neuropathol 2016 131 6 803 20 10.1007/s00401-016-1545-1 27157931
Louis DN, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016;131(6):803–20.27157931 10.1007/s00401-016-1545-1
3. Topalian SL Safety, activity, and immune correlates of anti-PD-1 antibody in cancer N Engl J Med 2012 366 26 2443 54 10.1056/NEJMoa1200690 22658127
Topalian SL, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443–54.22658127 10.1056/NEJMoa1200690
4. Rogachev AD et al. Correlation of metabolic profiles of plasma and Cerebrospinal Fluid of High-Grade Glioma patients. Metabolites, 2021. 11(3).
5. Lah TT Novak M Breznik B Brain malignancies: Glioblastoma and brain metastases Semin Cancer Biol 2020 60 262 73 10.1016/j.semcancer.2019.10.010 31654711
Lah TT, Novak M, Breznik B. Brain malignancies: Glioblastoma and brain metastases. Semin Cancer Biol. 2020;60:262–73.31654711 10.1016/j.semcancer.2019.10.010
6. Tashjian RS Vinters HV Yong WH Biobanking of Cerebrospinal Fluid Methods Mol Biol 2019 1897 107 14 10.1007/978-1-4939-8935-5_11 30539439
Tashjian RS, Vinters HV, Yong WH. Biobanking of Cerebrospinal Fluid. Methods Mol Biol. 2019;1897:107–14.30539439 10.1007/978-1-4939-8935-5_11
7. Simrén J Fluid biomarkers in Alzheimer’s disease Adv Clin Chem 2023 112 249 81 10.1016/bs.acc.2022.09.006 36642485
Simrén J, et al. Fluid biomarkers in Alzheimer’s disease. Adv Clin Chem. 2023;112:249–81.36642485 10.1016/bs.acc.2022.09.006
8. Deisenhammer F The cerebrospinal fluid in multiple sclerosis Front Immunol 2019 10 726 10.3389/fimmu.2019.00726 31031747
Deisenhammer F, et al. The cerebrospinal fluid in multiple sclerosis. Front Immunol. 2019;10:726.31031747 10.3389/fimmu.2019.00726
9. Kopková A MicroRNAs in cerebrospinal fluid as biomarkers in Brain Tumor patients Klin Onkol 2019 32 3 181 6 10.14735/amko2019181 31216849
Kopková A, et al. MicroRNAs in cerebrospinal fluid as biomarkers in Brain Tumor patients. Klin Onkol. 2019;32(3):181–6.31216849 10.14735/amko2019181
10. Im JH Comparative cerebrospinal fluid metabolites profiling in glioma patients to predict malignant transformation and leptomeningeal metastasis with a potential for preventive personalized medicine Epma j 2020 11 3 469 84 10.1007/s13167-020-00211-4 32849928
Im JH, et al. Comparative cerebrospinal fluid metabolites profiling in glioma patients to predict malignant transformation and leptomeningeal metastasis with a potential for preventive personalized medicine. Epma j. 2020;11(3):469–84.32849928 10.1007/s13167-020-00211-4
11. Sekula P Mendelian randomization as an Approach to assess causality using Observational Data J Am Soc Nephrol 2016 27 11 3253 65 10.1681/ASN.2016010098 27486138
Sekula P, et al. Mendelian randomization as an Approach to assess causality using Observational Data. J Am Soc Nephrol. 2016;27(11):3253–65.27486138 10.1681/ASN.2016010098
12. Panyard DJ Cerebrospinal fluid metabolomics identifies 19 brain-related phenotype associations Commun Biol 2021 4 1 63 10.1038/s42003-020-01583-z 33437055
Panyard DJ, et al. Cerebrospinal fluid metabolomics identifies 19 brain-related phenotype associations. Commun Biol. 2021;4(1):63.33437055 10.1038/s42003-020-01583-z
13. Yang J Assessing the Causal effects of human serum metabolites on 5 Major Psychiatric disorders Schizophr Bull 2020 46 4 804 13 10.1093/schbul/sbz138 31919502
Yang J, et al. Assessing the Causal effects of human serum metabolites on 5 Major Psychiatric disorders. Schizophr Bull. 2020;46(4):804–13.31919502 10.1093/schbul/sbz138
14. Flatby HM Circulating levels of micronutrients and risk of infections: a mendelian randomization study BMC Med 2023 21 1 84 10.1186/s12916-023-02780-3 36882828
Flatby HM, et al. Circulating levels of micronutrients and risk of infections: a mendelian randomization study. BMC Med. 2023;21(1):84.36882828 10.1186/s12916-023-02780-3
15. Maan M Lipid metabolism and lipophagy in cancer Biochem Biophys Res Commun 2018 504 3 582 9 10.1016/j.bbrc.2018.02.097 29438712
Maan M, et al. Lipid metabolism and lipophagy in cancer. Biochem Biophys Res Commun. 2018;504(3):582–9.29438712 10.1016/j.bbrc.2018.02.097
16. Halama A Nesting of colon and ovarian cancer cells in the endothelial niche is associated with alterations in glycan and lipid metabolism Sci Rep 2017 7 39999 10.1038/srep39999 28051182
Halama A, et al. Nesting of colon and ovarian cancer cells in the endothelial niche is associated with alterations in glycan and lipid metabolism. Sci Rep. 2017;7:39999.28051182 10.1038/srep39999
17. Heverin M Crossing the barrier: net flux of 27-hydroxycholesterol into the human brain J Lipid Res 2005 46 5 1047 52 10.1194/jlr.M500024-JLR200 15741649
Heverin M, et al. Crossing the barrier: net flux of 27-hydroxycholesterol into the human brain. J Lipid Res. 2005;46(5):1047–52.15741649 10.1194/jlr.M500024-JLR200
18. Saeed A 7α-hydroxy-3-oxo-4-cholestenoic acid in cerebrospinal fluid reflects the integrity of the blood-brain barrier J Lipid Res 2014 55 2 313 8 10.1194/jlr.P044982 24319290
Saeed A, et al. 7α-hydroxy-3-oxo-4-cholestenoic acid in cerebrospinal fluid reflects the integrity of the blood-brain barrier. J Lipid Res. 2014;55(2):313–8.24319290 10.1194/jlr.P044982
19. Feng Y Causal effects of genetically determined metabolites on cancers included lung, breast, ovarian cancer, and glioma: a mendelian randomization study Transl Lung Cancer Res 2022 11 7 1302 14 10.21037/tlcr-22-34 35958335
Feng Y, et al. Causal effects of genetically determined metabolites on cancers included lung, breast, ovarian cancer, and glioma: a mendelian randomization study. Transl Lung Cancer Res. 2022;11(7):1302–14.35958335 10.21037/tlcr-22-34
20. Karim MR Butyrate’s (a short-chain fatty acid) microbial synthesis, absorption, and preventive roles against colorectal and lung cancer Arch Microbiol 2024 206 4 137 10.1007/s00203-024-03834-7 38436734
Karim MR, et al. Butyrate’s (a short-chain fatty acid) microbial synthesis, absorption, and preventive roles against colorectal and lung cancer. Arch Microbiol. 2024;206(4):137.38436734 10.1007/s00203-024-03834-7
21. Yao JZ et al. Diagnostics Ovarian cancer via Metabolite Anal Mach Learn Integr Biol (Camb), 2023. 15.
22. Murín R Glial metabolism of valine Neurochem Res 2009 34 7 1195 203 10.1007/s11064-008-9895-2 19127430
Murín R, et al. Glial metabolism of valine. Neurochem Res. 2009;34(7):1195–203.19127430 10.1007/s11064-008-9895-2
23. Bel’skaya LV, Sarf EA, Loginova AI. Diagn Value Salivary Amino Acid Levels Cancer Metabolites, 2023. 13(8).
24. Lin J Plasma cysteinylglycine levels and breast cancer risk in women Cancer Res 2007 67 23 11123 7 10.1158/0008-5472.CAN-07-3061 18056435
Lin J, et al. Plasma cysteinylglycine levels and breast cancer risk in women. Cancer Res. 2007;67(23):11123–7.18056435 10.1158/0008-5472.CAN-07-3061
25. Miranti EH Prospective study of serum cysteine and cysteinylglycine and cancer of the head and neck, esophagus, and stomach in a cohort of male smokers Am J Clin Nutr 2016 104 3 686 93 10.3945/ajcn.115.125799 27534643
Miranti EH, et al. Prospective study of serum cysteine and cysteinylglycine and cancer of the head and neck, esophagus, and stomach in a cohort of male smokers. Am J Clin Nutr. 2016;104(3):686–93.27534643 10.3945/ajcn.115.125799
26. Du W UPP1 enhances bladder cancer progression and gemcitabine resistance through AKT Int J Biol Sci 2024 20 4 1389 409 10.7150/ijbs.83774 38385072
Du W, et al. UPP1 enhances bladder cancer progression and gemcitabine resistance through AKT. Int J Biol Sci. 2024;20(4):1389–409.38385072 10.7150/ijbs.83774
27. Li HY Separation and identification of purine nucleosides in the urine of patients with malignant cancer by reverse phase liquid chromatography/electrospray tandem mass spectrometry J Mass Spectrom 2009 44 5 641 51 10.1002/jms.1539 19142897
Li HY, et al. Separation and identification of purine nucleosides in the urine of patients with malignant cancer by reverse phase liquid chromatography/electrospray tandem mass spectrometry. J Mass Spectrom. 2009;44(5):641–51.19142897 10.1002/jms.1539
28. Zhao L Stachydrine ameliorates isoproterenol-induced cardiac hypertrophy and fibrosis by suppressing inflammation and oxidative stress through inhibiting NF-κB and JAK/STAT signaling pathways in rats Int Immunopharmacol 2017 48 102 9 10.1016/j.intimp.2017.05.002 28499193
Zhao L, et al. Stachydrine ameliorates isoproterenol-induced cardiac hypertrophy and fibrosis by suppressing inflammation and oxidative stress through inhibiting NF-κB and JAK/STAT signaling pathways in rats. Int Immunopharmacol. 2017;48:102–9.28499193 10.1016/j.intimp.2017.05.002
29. Bao X Stachydrine hydrochloride inhibits hepatocellular carcinoma progression via LIF/AMPK axis Phytomedicine 2022 100 154066 10.1016/j.phymed.2022.154066 35366490
Bao X, et al. Stachydrine hydrochloride inhibits hepatocellular carcinoma progression via LIF/AMPK axis. Phytomedicine. 2022;100:154066.35366490 10.1016/j.phymed.2022.154066
30. Wang M Stachydrine hydrochloride inhibits proliferation and induces apoptosis of breast cancer cells via inhibition of akt and ERK pathways Am J Transl Res 2017 9 4 1834 44 28469788
Wang M, et al. Stachydrine hydrochloride inhibits proliferation and induces apoptosis of breast cancer cells via inhibition of akt and ERK pathways. Am J Transl Res. 2017;9(4):1834–44.28469788
31. Liu FC et al. The modulation of Phospho-Extracellular Signal-regulated kinase and phospho-protein kinase B Signaling pathways plus Activity of Macrophage-stimulating protein contribute to the Protective Effect of Stachydrine on Acetaminophen-Induced Liver Injury. Int J Mol Sci, 2024. 25(3).
32. Mai M Serum levels of acylcarnitines are altered in prediabetic conditions PLoS ONE 2013 8 12 e82459 10.1371/journal.pone.0082459 24358186
Mai M, et al. Serum levels of acylcarnitines are altered in prediabetic conditions. PLoS ONE. 2013;8(12):e82459.24358186 10.1371/journal.pone.0082459
33. Taylor K et al. The relationship of maternal gestational Mass spectrometry-derived metabolites with offspring congenital heart disease: results from multivariable and mendelian randomization analyses. J Cardiovasc Dev Dis, 2022. 9(8).
34. Kim H Yokoyama W Davis PA TRAMP prostate tumor growth is slowed by walnut diets through altered IGF-1 levels, energy pathways, and cholesterol metabolism J Med Food 2014 17 12 1281 6 10.1089/jmf.2014.0061 25354213
Kim H, Yokoyama W, Davis PA. TRAMP prostate tumor growth is slowed by walnut diets through altered IGF-1 levels, energy pathways, and cholesterol metabolism. J Med Food. 2014;17(12):1281–6.25354213 10.1089/jmf.2014.0061
